77 search results for lung cancer
Clinical Guidelines Translations
) Multiple Myeloma Version 5.2022 (Arabic) Non-Small Cell Lung Cancer Version, (Chinese) Breast Cancer Version 4.2022 (Chinese) Central Nervous System Cancers, Cancer Version 4.2022 (Chinese) Small Cell Lung Cancer Version 1.2023 (Chinese, ) Multiple Myeloma Version 5.2022 (French) Non-Small Cell Lung Cancer Version, ) Multiple Myeloma Version 5.2022 (Italian) Non-Small Cell Lung Cancer Version 3.2023
https://www.nccn.org/global/what-we-do/clinical-guidelines-translationsBiomarkers Compendium Reviewer Acknowledgment
Kettering Cancer Center Biliary Tract Cancers Lawrence J. Jennings, Lung Cancer Dara L. Aisner, PhD, MD, UCLA Jonsson Comprehensive Cancer Center Pediatric Central Nervous System Cancers, Small Cell Lung Cancer Cesar A. Moran, MD, Diller Family Comprehensive Cancer Center Acute Myeloid Leukemia
https://www.nccn.org/compendia-templates/compendia/biomarkers-compendium/biomarkers-compendium-reviewer-acknowledgmentGuidelines for Patients Translations
® Non-Small Cell Lung Cancer - Early and Locally Advanced Version 2024 (Arabic) Guidelines for Patients® Non-Small Cell Lung Cancer - Metastatic Version 2024 (Arabic, Cancer: Early Stage Version 2024 (Arabic) Guidelines for Patients® Small Cell Lung Cancer, -Small Cell Lung Cancer - Early and Locally Advanced Version 2024 (Chinese) Guidelines for Patients® Non-Small Cell Lung Cancer - Metastatic Version 2024 (Chinese) Guidelines
https://www.nccn.org/global/what-we-do/guidelines-for-patients-translationsInternational Adaptations
-Small Cell Lung Cancer Version 3.2022 (English) Ovarian Cancer/Fallopian Tube Cancer, Cancers Version 2.2021 (English) Cervical Cancer Version 1.2021 (English) Colon Cancer Version 2.2022 (English) Head and Neck Cancers Version, in the specific country/region at this time. Brazil Editions Prostate Cancer Version 4.2024 (English) China Editions Cervical Cancer Version
https://www.nccn.org/global/what-we-do/international-adaptationsClinical Trials
Cancers Namrata Vijayvergia, MD Fox Chase Cancer Center A Multi-Center Phase I trial of Neratinib and fam-trastuzumab deruxtecan in advanced refractory gastrointestinal cancer patients Lung Cancer Yasir, EGFR Mutant Lung Cancer Nicholas Bodor, MD, PhD, MPH Fox Chase Cancer Center TH-138: Phase II, Select a cancer below for additional information on ORP active trials at NCCN Member Institutions. Gastrointestinal Scott Plotkin, MD Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts
https://www.nccn.org/education-research/nccn-oncology-research-program/clinical-trialsHIT
Tract Cancers Bladder Cancer Bone Cancer Breast Cancer Castleman Disease Central Nervous System Cancers Cervical Cancer Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Chronic Myeloid, Cancers Gastric Cancer Gastrointestinal Stromal Tumors Gestational Trophoblastic Neoplasia Hairy, Pediatric Central Nervous System Cancers Pediatric Hodgkin Lymphoma Penile Cancer Primary Cutaneous Lymphomas Prostate Cancer Rectal Cancer Small Bowel Adenocarcinoma Small Cell Lung Cancer
https://www.nccn.org/redirects/hitGuidelines Panels
Lung Cancer Screening Panel, Panel Non-Small Cell Lung Cancer, Small Cell Lung Cancer Panel, Adult Cancer Pain Panel, Bladder/Penile Cancers Panel
https://www.nccn.org/guidelines/guidelines-panels-and-disclosure/disclosure-panelsPermission to Cite or Use NCCN Content
Anal Carcinoma Antiemesis Basal Cell Skin Cancer B-Cell Lymphomas Biliary Tract Cancers Bladder, Fatigue Castleman Disease Central Nervous System Cancers Cervical Cancer Chronic Lymphocytic, Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma Kidney Cancer Lung Cancer Screening, Myeloproliferative Neoplasms Neuroblastoma Neuroendocrine and Adrenal Tumors Non-Small Cell Lung Cancer Occult, Cancer Prostate Cancer Early Detection Rectal Cancer Small Bowel Adenocarcinoma Small Cell Lung
https://www.nccn.org/guidelines/permission-to-cite-or-use-nccn-contentResume Screening
Adenocarcinoma Anal Carcinoma Basal Cell Skin Cancer B-Cell Lymphomas Biliary Tract Cancers Bladder Cancer Bone Cancer Breast Cancer Castleman Disease Central Nervous System Cancers Cervical, Cancer Dermatofibrosarcoma Protuberans Esophageal and Esophagogastric Junction Cancers Gastric Cancer, Neoplasms Neuroblastoma Neuroendocrine and Adrenal Tumors Non-Small Cell Lung Cancer Occult Primary, Nervous System Cancers Pediatric Hodgkin Lymphoma Penile Cancer Primary Cutaneous Lymphomas
https://www.nccn.org/covid-19/resume-screeningGuidelines for Patients
Version: 2022 Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer - Metastatic Version: 2024, Small Cell Lung Cancer Version: 2024, Version: 2025 Lung Cancer Screening, resources, lung cancer resources, immunotherapy information, lung cancer information, prostate cancer
https://www.nccn.org/patientresources/patient-resources/guidelines-for-patientsAnnual Report
/cancercenters. NCCN Member Institutions Mayo Clinic Comprehensive Cancer Center UC Davis Case, for Breast Cancer 1,318,623 Downloads NCCN Guidelines for Non-Small Cell Lung Cancer 932,195, Cell Lung Cancer are currently available in English and Vietnamese. NCCN 2024 Annual Report 18, at meetings including: - World Conference on Lung Cancer - American Association for Cancer Research, The University of Texas MD Anderson Cancer Center Improving The Detection of Other Cancers in Patients
https://www.nccn.org/docs/default-source/about/annual-report.pdf?sfvrsn=8411082_40Harmonized Guidelines
3.2024 Biliary Tract Cancers Version 3.2023 Bladder Cancer Version 1.2023, Cancers Version 2.2022 Cervical Cancer Version 1.2023 Chronic Lymphocytic, Colon Cancer Version 2.2022 Esophageal and Esophagogastric Junction Cancers Version, and Adrenal Tumors Version 1.2022 Non-Small Cell Lung Cancer Version 4.2024 Occult, Pediatric Central Nervous System Cancers Version 1.2024 Penile Cancer Version
https://www.nccn.org/global/what-we-do/harmonized-guidelinesORP Grant History
lung cancer AstraZeneca Pharmaceuticals, LP – quality improvement/ projects in ovarian cancer AstraZeneca Pharmaceuticals, LP – quality improvement/ projects in small cell lung cancer AstraZeneca Pharmaceuticals, LP – quality improvement/ projects in early-stage non-small cell lung cancer, with afatinib in lung cancer Bristol-Myers Squibb Company and ImClone Systems Incorporated, , and bevaciumab, with or without atezolizumab, in lung cancer GlaxoSmithKline LLC – pre-clinical
https://www.nccn.org/education-research/nccn-oncology-research-program/orp-grant-historyTreatment by Cancer Type
Treatment by Cancer Type, Cancers Version: 2025 Lung Cancer Screening, Cancer Resources All Lung Cancer Resources All Non-Hodgkin Lymphomas (NHL) Resources, Non-Small Cell Lung Cancer - Early and Locally Advanced Version: 2024 Non-Small Cell Lung Cancer - Metastatic, : 2024 Small Cell Lung Cancer Version: 2024
https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/treatment-by-cancer-typeDetection, Prevention, and Risk Reduction
Cancers Version: 2025 Lung Cancer Screening, Cancer Resources All Lung Cancer Resources All Non-Hodgkin Lymphomas (NHL) Resources, Non-Small Cell Lung Cancer - Early and Locally Advanced Version: 2024 Non-Small Cell Lung Cancer - Metastatic, : 2024 Small Cell Lung Cancer Version: 2024
https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/detection-prevention-and-risk-reductionSupportive Care
Cancers Version: 2025 Lung Cancer Screening, Cancer Resources All Lung Cancer Resources All Non-Hodgkin Lymphomas (NHL) Resources, Non-Small Cell Lung Cancer - Early and Locally Advanced Version: 2024 Non-Small Cell Lung Cancer - Metastatic, : 2024 Small Cell Lung Cancer Version: 2024
https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/supportive-careSpecific Populations
Cancers Version: 2025 Lung Cancer Screening, Cancer Resources All Lung Cancer Resources All Non-Hodgkin Lymphomas (NHL) Resources, Non-Small Cell Lung Cancer - Early and Locally Advanced Version: 2024 Non-Small Cell Lung Cancer - Metastatic, : 2024 Small Cell Lung Cancer Version: 2024
https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients/specific-populationsCurrent Opportunities
Cancers Bladder Cancer Bone Cancer Breast Cancer Castleman Disease Central Nervous System Cancers Cervical Cancer Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Chronic Myeloid Leukemia Colon Cancer Dermatofibrosarcoma Protuberans Esophageal and Esophagogastric Junction Cancers, Myeloproliferative Neoplasms Neuroblastoma Neuroendocrine and Adrenal Tumors Non-Small Cell Lung Cancer, Pediatric Central Nervous System Cancers Pediatric Hodgkin Lymphoma Penile Cancer Primary Cutaneous
https://www.nccn.org/education-research/nccn-oncology-research-program/current-opportunitiesTransparency Process
/Penile Cancers Panel Version: 1.2025 ( Penile Cancer ) Date, Adult Cancer Pain Panel Version: 1.2025 ( Adult Cancer, ( Adult Cancer Pain ) Date: 2024-03-06 Transparency Panel Disclosures/Attendance Version: 1.2024 ( Adult Cancer Pain ) Date: 2023-09-28 Transparency Panel Disclosures/Attendance Version: 1.2023 ( Adult Cancer Pain ) Date: 2022-09-12 Transparency
https://www.nccn.org/guidelines/guidelines-process/transparency-process-and-recommendationsNational Comprehensive Cancer Network - Home
National Comprehensive Cancer Network - Home, pancreatic cancer, combination regimens for advanced EGFR-mutant lung cancer, barriers and opportunities, Patient Webinar: Small Cell Lung Cancer, to developing programs and products to enhance cancer care globally. JNCCN Now available, neoadjuvant therapy in breast cancer, survivorship in older men with prostate cancer, and more, cancer care recommendations downloaded more than 16 million times annually and used across
https://www.nccn.org/home